HTLV-I carriers or patients with HTLV-I associated myelopathy (HAM)are prone to immune-mediated inflammatory disorders. Wepresent a 44-year-old female with HAMwho developed Graves' disease. She developed severe Graves' ophthalmopathy shortly after 131I therapy, concurrently with a remarkable increase in TSH-receptor antibody titer. Ophthalmopathy was aggravated in spite of prednisolone therapy and euthyroidism being maintained by thyroxine replacement. Uveitis also developed after 131I therapy and iridocyclitis finally required trabeculotomy. This case suggests that HAM patients may have a higher risk of immune-mediated Graves' ophthalmopathy after 131I therapy. (Internal Medicine 33: 564-568, 1994) 
Introduction
For the hyperthyroidism of Graves' disease, radioiodine (131I) therapy is popular. About 70% of patients with Graves' disease are treated by this method in the United States (1) , and about 20%and 10%receive such therapy in Europe and Japan, respectively (1) (2) (3) . Although adverse effects are usually negligible in radioiodine therapy, the developmentor aggravation of Graves' ophthalmopathy has been reported (4, 5) . Wepresent the case of a patient with HTLV-Iassociated myelopathy (HAM)who developed severe Graves' ophthalmopathy and uveitis after 13 1I therapy for hyperthyroidism. HAM,or tropical spastic paraparesis (TSP), is a spastic spinal paralysis due to HTLV-I infection (6, 7) . The geographic distribution ofHTLV-I infection is worldwide and the prevalence is strikingly high in southwest Japan, the Caribbean, Central Africa, and Melanesia. The mechanism by which spinal cord degeneration is caused by HTLV-I infection is considered to be immunologic (8, 9) . The association of Graves' disease with HAM is not incidental, because the incidence of manyother autoimmunediseases or immune-mediated diseases are high in HAM patients or HTLV-I carriers (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) .
We discuss the various mechanisms by which Graves' ophthalmopathy and uveitis may have developed or been aggravated after radioiodine therapy in this HAM patient.
Methods
Serum levels of total T4, T3, and TSH were measured by an immunofluorometric assay or immunoradiometric assay using commercially available kits. Free T4 (fT4) and free T3 (fT3)
were measured by a one-step analog-tracer-based radioimmunoassay (Amerlex-M Free T4 RIA and Free T3 RIA, Amersham Medical Ltd, Buckinghamshire, UK). The normal ranges ofT4, T3, fT4, rT3 and TSH were 80-140 nmol/1 (6-1 1 jLLg/dl), 1.3-3.1 nmol/1 (80-200 ng/dl), 1 1-28 pmol/1 (0.85-2. 15 ng/dl), 4.6-8.9 pmol/1 (3.0-5.8 pg/ml) and 0.04-4. 10 mU/ 1, respectively. Antithyroglobulin and antimicrosomal antibodies were examined by the particle-agglutination method (Serodia-ATG & Serodia-AMC, Fujirebio Inc., Tokyo, Japan). TSHbinding inhibiting immunoglobulins (TBII) were measured by their ability to inhibit 125I-TSH binding to solubilized porcine TSH receptors (TRAb Kit, RSR Limited, Cardiff, UK) (normal range: <10%). Both the thyroid stimulating antibody (TSAb) and TSH stimulation-blocking antibody (TSBAb) were measured using cultured porcine thyroid cells (24 serum was examined for the first time and found to be positive, i.e., 8, 192 xby the passive agglutination method and 1,280 xby the immunofluorescence method. HTLV-Iantibody was also positive in the cerebrospinal fluid ( l ,280x) by passive agglutination. Western blot analysis confirmed that HTLV-I antibody was present in both serum and cerebrospinal fluid. The diagnosis of HAMwas thus made. HerHLAtype was A24, A31; B51, B52; C blank; DR9, DR14. She began prednisolone (30 mg/ day) which was decreased later in a stepwise manner to the dose of 20 mg every other day. Despite this therapy, her spastic paraparesis gradually progressed. In April 1991, she noticed palpitation, diaphoresis and weight loss. She had a diffuse goiter of about 35 g in weight as estimated by palpation. Serum levels of T4, T3, fT4, and fT3 were 360 nmol/1 (28.0 jig/dl), 10.3 nmol/1 (672 ng/dl), 96 pmol/ 1 (7.43 ng/dl), and >23.0 pmol/1 (>15.0 pg/ml), respectively. The serum TSHwas suppressed to less than 0.022 mU/1. Both antithyroglobulin and antimicrosomal antibodies were positive (both 1:2,400). TSHreceptor antibodies were positive; TBII, thyroid stimulating and TSH stimulation-blocking antibodies were 37%, 223% and 19%, respectively. Thyroidal radioactive iodine uptake (RAIU) was 62% at 24 hours. She had only minimal eye signs of Graves' disease, i.e., decreased blinking due to increased sympathetic tone. The Hertel exophthalmometer showed no exophthalmos (15.0 mm,normal: <16 mmin Japanese) for both eyes. She had neither circumscribed myxoedema nor achropachy. Although these therapies were successful in achieving euthyroidism rather quickly, eye symptomsdeveloped after the 13ll therapies. After the first 131I treatment, she noticed right myodesopsia. A detailed ophthalmological examination revealed iridocyclitis which disappeared spontaneously in one month. However, two weeks after the second 131I treatment, she suffered from eye irritation and epiphora. Shortly afterward, exophthalmos, chemosis, conjunctival injection and swelling of the eyelids, which are typical of acute Graves' ophthalmopathy, developed. The Hertel exophthalmometer showed 21 mmon the right and 22 mmon the left. The oral prednisolone dose was increased from a daily dose of20 mg to 40 mg. In spite of the prednisolone therapy and maintaining euthyroidism, soft tissue involvement (pain, epiphora, chemosis, conjunctival injection and eye lid swelling) and exophthalmos progressed. disturbance. For the rapid aggravation of Graves' ophthalmopathy, the retrobulbar tissue was irradiated with 4 MVphotons (20 Gy). With this treatment, the soft tissue involvement and proptosis improved slightly (proptosis 23 mmon the right and 24 mmon the left). The dose of prednisolone was decreased because of the development of iatrogenic Cushing' s syndrome. After the decrease in the dose of prednisolone, the soft tissue involvement and proptosis was aggravated again (proptosis 24 mmon the right, 25 mmon the left) and severe uveitis developed in both eyes. The development ofuveitis required another increase in the dose of prednisolone.
On a large dose of prednisolone, the uveitis subsided gradually. However, the intraocular pressure increased in both eyes (56 mmHg on the right, 44 mmHg on the left) in a manner typical of secondary glaucoma. Various conservative ophthalmological treatments did not protect sufficiently the visual acuity and visual fields and, finally, trabeculotomy was performed for both eyes.
Discussion
The mechanism by which myelopathy develops in HTLV-I infection has been studied intensively and several lines of evidence suggest that some immune-mediated mechanism damages the central nervous system (8, 9) . The characteristics of immunological findings in HAMpatients mimic those observed in autoimmunediseases. They include the activation of polyclonal B lymphocytes (27) , the increase in activated T cells (28, 29) , the increased spontaneous proliferation of the peripheral blood lymphocytes (30-34), HLA-haplotype-linked high immuneresponsiveness against HTLV-I(35), and increased adherence of T cells to endothelial cells (36) . Further, the development of a wide variety of inflammatory lesions in organs other than the central nervous system in HAM patients or HTLV-I carriers has been reported.
These include bronchopneumopathy ( 10-1 2), polyarthritis ( 1 3-1 5), Sjogren ' s syndrome (16) , polymyositis (17, 18) , uveitis (19) (20) (21) , and chronic lymphocytic thyroiditis (22, 23) . Since a wide spectrum of multiorgan disorders may result, Maruyamaet al proposed designating HTLV-I associated complex (HAC) as a new clinical entity (37). Manyof these disorders are considered to be autoimmune. Therefore, it is speculated that HTLV-Iinfection may be involved in the development of autoimmune diseases. Therefore, the association of Graves' disease with
HAMin the present patient is not considered to be incidental. In the present patient, severe Graves' ophthalmopathy developed after 131I therapy. Although aggravation of Graves' ophthalmopathy after radioiodine therapy is known (4, 5) , severe ophthalmopathy is rare in Japan even after radioiodine therapy (38, 39). Therefore, the development of severe ophthalmopathy after radioiodine therapy in the present patient deserves special mention. Graves' ophthalmopathy is also an immune-mediated disorder of extraocular muscles and retrobulbar connective tissue. Although the precise immunological relationship between retrobulbar inflammation and thyroiditis is unclear, it has been hypothesized that the release of antigens from the thyroid gland causes an immuneresponse which also provokes the inflammation of orbital tissue, probably because there is antigen similarity between the tissues. Thus, the destruction of thyroid follicles by radioiodine has the potential risk of exposing antigens to the immunesystem and provoking an autoimmune reaction. In fact, the increase in TSHreceptor antibody after radioiodine therapy, which was also seen in the present patient (Fig. 2) , is a well known phenomenon (40, 41). B artalena and colleagues reported that prednisolone treatment is useful as a prophylaxis against the aggravation of Graves' ophthalmopathy after 131I therapy (4). The present patient had been taking a daily dose of 20 mg of prednisolone when she developed Graves ' ophthalmopathy. Hypothyroidism produced by treatment for hyperthyroidism is also knownto aggravate Graves' ophthalmopathy (42). It is speculated that the increased TSHstimulates the thyroid gland to express and release antigens whichprovokeautoimmune reactions against retrobulbar tissue. In the present patient, TSH was increased after both 131I therapies. The increase in TSH after the first 13 1I treatment was very transient and was followed by the relapse ofthyrotoxicosis. TSHwas increased again after the second 131I treatment and then normalized by thyroxine replacement. It was difficult to prevent the TSHincrease in the present case because it increased very rapidly after the 131I
therapies. These episodes of increase in TSHmay have aggravated the Graves' ophthalmopathy in the present patient. The development of severe Graves' ophthalmopathy in the present HAM patient suggests that hyperthyroidism should be treated carefully so as not to stimulate the autoimmunemechanism of Graves' disease, particularly in HAMpatients or HTLV-Icarriers, because these patients may have a higher risk for autoimmune-mediated provocation of ophthalmopathy. The uveitis which also developed after radioiodine therapy in the present patient may not have been influenced by radioiodine therapy because uveitis is not a rare disease in the HTLV-I associated complex (19) (20) (21) . However, it is probable that the underlying uveitis was affected adversely by the severe Graves ' ophthalmopathy. In the present patient, refractory iridocyclitis and large dose prednisolone therapy finally induced bilateral glaucoma that required trabeculotomy.
